CN103491777B - 组织蛋白酶c抑制剂 - Google Patents
组织蛋白酶c抑制剂 Download PDFInfo
- Publication number
- CN103491777B CN103491777B CN201280017698.7A CN201280017698A CN103491777B CN 103491777 B CN103491777 B CN 103491777B CN 201280017698 A CN201280017698 A CN 201280017698A CN 103491777 B CN103491777 B CN 103491777B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compounds
- compound
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OMKWRQOMPURHGF-UHFFFAOYSA-N C1C(C=CCC2)=C2NC1 Chemical compound C1C(C=CCC2)=C2NC1 OMKWRQOMPURHGF-UHFFFAOYSA-N 0.000 description 1
- JRSYYLJDKVSNJH-VOTSOKGWSA-N CC(/C=C/C(OC)=O)NC(OC(C)(C)C)=O Chemical compound CC(/C=C/C(OC)=O)NC(OC(C)(C)C)=O JRSYYLJDKVSNJH-VOTSOKGWSA-N 0.000 description 1
- PKYNXZQRAKLAOU-QXZGNRNASA-N CC[C@@H](/C=C/C(N(CC1)c2c1cccc2)=O)NC(O)OC(C)(C)C Chemical compound CC[C@@H](/C=C/C(N(CC1)c2c1cccc2)=O)NC(O)OC(C)(C)C PKYNXZQRAKLAOU-QXZGNRNASA-N 0.000 description 1
- PKTSVTHTHOHXBQ-CZEYKFRCSA-N CC[C@@H](/C=C/C(O)=O)NC(OC(C)(C)C)=O Chemical compound CC[C@@H](/C=C/C(O)=O)NC(OC(C)(C)C)=O PKTSVTHTHOHXBQ-CZEYKFRCSA-N 0.000 description 1
- BOUJRTUVSGNZPU-LURJTMIESA-N CC[C@@H](C(N)=O)NC(OC(C)(C)C)=O Chemical compound CC[C@@H](C(N)=O)NC(OC(C)(C)C)=O BOUJRTUVSGNZPU-LURJTMIESA-N 0.000 description 1
- AVMVBGPMNRUGCR-JAMMHHFISA-N CC[C@@H](C(NOC)O)NC(OC(C)(C)C)=O Chemical compound CC[C@@H](C(NOC)O)NC(OC(C)(C)C)=O AVMVBGPMNRUGCR-JAMMHHFISA-N 0.000 description 1
- NBDAUFXJXMBQRC-ZETCQYMHSA-N CC[C@@H](C=O)NC(OC(C)(C)C)=O Chemical compound CC[C@@H](C=O)NC(OC(C)(C)C)=O NBDAUFXJXMBQRC-ZETCQYMHSA-N 0.000 description 1
- ZCAIYDCCLGLTRJ-UHFFFAOYSA-N COC(C=P(C1=CC=CCC1)(c1ccccc1)c1ccccc1)=O Chemical compound COC(C=P(C1=CC=CCC1)(c1ccccc1)c1ccccc1)=O ZCAIYDCCLGLTRJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441840P | 2011-02-11 | 2011-02-11 | |
| US61/441,840 | 2011-02-11 | ||
| PCT/US2012/024428 WO2012109415A1 (en) | 2011-02-11 | 2012-02-09 | Cathepsin c inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103491777A CN103491777A (zh) | 2014-01-01 |
| CN103491777B true CN103491777B (zh) | 2015-05-06 |
Family
ID=46638952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280017698.7A Expired - Fee Related CN103491777B (zh) | 2011-02-11 | 2012-02-09 | 组织蛋白酶c抑制剂 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8841463B2 (enExample) |
| EP (1) | EP2672821B9 (enExample) |
| JP (1) | JP5931929B2 (enExample) |
| KR (1) | KR20140048857A (enExample) |
| CN (1) | CN103491777B (enExample) |
| AR (1) | AR085163A1 (enExample) |
| AU (1) | AU2012214405B2 (enExample) |
| BR (1) | BR112013020510A2 (enExample) |
| CA (1) | CA2827157A1 (enExample) |
| CL (1) | CL2013002325A1 (enExample) |
| CO (1) | CO6741219A2 (enExample) |
| DO (1) | DOP2013000182A (enExample) |
| EA (1) | EA023168B1 (enExample) |
| ES (1) | ES2583091T3 (enExample) |
| IL (1) | IL227814A0 (enExample) |
| MA (1) | MA34961B1 (enExample) |
| MX (1) | MX2013009279A (enExample) |
| PE (1) | PE20140999A1 (enExample) |
| PH (1) | PH12013501665A1 (enExample) |
| SG (1) | SG192669A1 (enExample) |
| TW (1) | TW201302736A (enExample) |
| UY (1) | UY33905A (enExample) |
| WO (1) | WO2012109415A1 (enExample) |
| ZA (1) | ZA201306074B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| KR20180119582A (ko) * | 2016-02-12 | 2018-11-02 | 파맥시스 엘티디 | 라이실 옥시다제의 인돌 및 아자인돌 할로알릴아민 유도체 억제제 및 이의 용도 |
| AU2023296161A1 (en) | 2022-06-13 | 2025-01-02 | Alivexis, Inc. | Azacycloalkyl carbonyl cyclic amine compound |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212158A (en) * | 1987-11-03 | 1993-05-18 | Inorgan Sa Recherche & Developpement Pharmaceutiques, Cas | Derivatives of l-proline, their preparation and their biological uses |
| CN1240355A (zh) * | 1996-05-01 | 2000-01-05 | 伊莱利利公司 | 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途 |
| US20020107266A1 (en) * | 2000-12-12 | 2002-08-08 | Marguerita Lim-Wilby | Compounds, compositions and methods for treatment of parasitic infections |
| CN101675052A (zh) * | 2007-04-12 | 2010-03-17 | 辉瑞大药厂 | 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物 |
| US20100286118A1 (en) * | 2009-05-07 | 2010-11-11 | Rhonan Ford | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| WO2011019801A1 (en) * | 2009-08-12 | 2011-02-17 | Glaxo Group Limited | Cathepsin c inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| US6214799B1 (en) | 1996-05-14 | 2001-04-10 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
-
2012
- 2012-02-09 ES ES12744272.1T patent/ES2583091T3/es active Active
- 2012-02-09 UY UY0001033905A patent/UY33905A/es unknown
- 2012-02-09 JP JP2013553538A patent/JP5931929B2/ja not_active Expired - Fee Related
- 2012-02-09 WO PCT/US2012/024428 patent/WO2012109415A1/en not_active Ceased
- 2012-02-09 PE PE2013001836A patent/PE20140999A1/es not_active Application Discontinuation
- 2012-02-09 TW TW101104141A patent/TW201302736A/zh unknown
- 2012-02-09 PH PH1/2013/501665A patent/PH12013501665A1/en unknown
- 2012-02-09 MA MA36229A patent/MA34961B1/fr unknown
- 2012-02-09 SG SG2013060165A patent/SG192669A1/en unknown
- 2012-02-09 US US13/984,061 patent/US8841463B2/en not_active Expired - Fee Related
- 2012-02-09 KR KR1020137023618A patent/KR20140048857A/ko not_active Ceased
- 2012-02-09 CN CN201280017698.7A patent/CN103491777B/zh not_active Expired - Fee Related
- 2012-02-09 MX MX2013009279A patent/MX2013009279A/es not_active Application Discontinuation
- 2012-02-09 CA CA2827157A patent/CA2827157A1/en not_active Abandoned
- 2012-02-09 EA EA201391155A patent/EA023168B1/ru not_active IP Right Cessation
- 2012-02-09 AU AU2012214405A patent/AU2012214405B2/en not_active Ceased
- 2012-02-09 EP EP12744272.1A patent/EP2672821B9/en active Active
- 2012-02-09 BR BR112013020510A patent/BR112013020510A2/pt not_active IP Right Cessation
- 2012-02-10 AR ARP120100455A patent/AR085163A1/es unknown
-
2013
- 2013-08-05 IL IL227814A patent/IL227814A0/en unknown
- 2013-08-09 DO DO2013000182A patent/DOP2013000182A/es unknown
- 2013-08-09 CO CO13190045A patent/CO6741219A2/es unknown
- 2013-08-09 CL CL2013002325A patent/CL2013002325A1/es unknown
- 2013-08-13 ZA ZA2013/06074A patent/ZA201306074B/en unknown
-
2014
- 2014-08-21 US US14/464,734 patent/US9187461B2/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212158A (en) * | 1987-11-03 | 1993-05-18 | Inorgan Sa Recherche & Developpement Pharmaceutiques, Cas | Derivatives of l-proline, their preparation and their biological uses |
| CN1240355A (zh) * | 1996-05-01 | 2000-01-05 | 伊莱利利公司 | 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途 |
| US20020107266A1 (en) * | 2000-12-12 | 2002-08-08 | Marguerita Lim-Wilby | Compounds, compositions and methods for treatment of parasitic infections |
| CN101675052A (zh) * | 2007-04-12 | 2010-03-17 | 辉瑞大药厂 | 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物 |
| US20100286118A1 (en) * | 2009-05-07 | 2010-11-11 | Rhonan Ford | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| WO2011019801A1 (en) * | 2009-08-12 | 2011-02-17 | Glaxo Group Limited | Cathepsin c inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230120254A1 (en) | Nitrile-Containing Antiviral Compounds | |
| CN103814028B (zh) | 作为组织蛋白酶c抑制剂的取代的n-[1-氰基-2-(苯基)乙基]-2-氮杂双环[2.2.1]庚烷-3-甲酰胺 | |
| BRPI0110955B1 (pt) | derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos. | |
| JP2010519328A (ja) | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 | |
| JP2022188014A (ja) | バニン阻害剤としてのヘテロ芳香族化合物 | |
| EA029030B1 (ru) | Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i | |
| CN103491777B (zh) | 组织蛋白酶c抑制剂 | |
| WO2014091443A1 (en) | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis | |
| ES2626246T3 (es) | Derivado de 8-oxodihidropurina | |
| CN113195515A (zh) | 新的二肽类化合物及其用途 | |
| WO2011025799A1 (en) | Cathepsin c inhibitors | |
| JPWO2009041475A1 (ja) | ピラゾール−３−イル−ベンズアミド誘導体の製造方法 | |
| KR20120061870A (ko) | 카텝신 ｃ 억제제 | |
| NZ614540B2 (en) | Cathepsin c inhibitors | |
| WO2012112733A1 (en) | Cathepsin c inhibitors | |
| OA20440A (en) | Nitrile-containing antiviral compounds | |
| EA045146B1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| TW200302724A (en) | Piperiding derivative compound and pharmaceuticals containing same as active ingredient | |
| WO2001010844A1 (fr) | DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE | |
| OA21481A (en) | Nitrile-containing antiviral compounds. | |
| CN101296924A (zh) | 作为p38激酶抑制剂的吡唑异喹啉脲衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150506 Termination date: 20180209 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |